Curbside Immunoassay Device for Quantitative Measurement of Cannabis Intoxication
用于定量测量大麻中毒的路边免疫测定装置
基本信息
- 批准号:9141902
- 负责人:
- 金额:$ 22.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-04-01 至 2017-03-31
- 项目状态:已结题
- 来源:
- 关键词:AirAntibodiesAreaBiocompatible MaterialsBiological AssayBiotinBloodBlood specimenBuffersCannabisCaymansChemicalsCollaborationsDetectionDevicesDiagnosisDrug AddictionDrug KineticsDrug abuseEnzymesExhibitsFoundationsHalf-LifeHourImmunoassayIntoxicationLaboratoriesLateralLaw EnforcementLinkLiquid substanceLogisticsMagnetic nanoparticlesMarijuanaMeasurementMeasuresMethodsMicrofluidicsMovementOpticsOralPatternPhaseReactionReagentReproducibilityResearch PersonnelRoboticsRouteRunningSafetySalivaSamplingSensitivity and SpecificitySerumSiteSmall Business Innovation Research GrantStatutes and LawsStreptavidinSubstance Use DisorderTHC concentrationTechnologyTestingTetrahydrocannabinolTimeUrineValidationWorkWorkplaceantibody conjugatebasedesigndrug testingfield studyinnovationinnovative technologiesmarijuana legalizationmarijuana usemeterminimally invasivenovelparticlephase 2 studyprogramspublic health relevanceresearch clinical testingtool
项目摘要
DESCRIPTION (provided by applicant): Law enforcement officials, workplace drug testing programs, and researchers in the field of drug abuse lack rapid, easily deployable tools to measure present cannabis (marijuana) intoxication. The enzyme-linked immunosorbant assay (ELISA) is an established cannabis testing method for detecting delta-9-tetrahydrocannabinol (THC) levels in urine or blood; however, the logistics of obtaining urine or blood samples on site represents a major limitation of current THC ELISAs, particularly for curbside testing of drivers. The most feasible candidate sample for curbside testing is the oral fluid, as it is a minimally invasive sampling route and the pharmacokinetics of THC concentration in oral fluid (half-life of 1.5 hours) parallels that of serum; however, the primary obstacle to this approach is the lack of a rapid, quantitative THC immunoassay. Traditional plate-based ELISA tests can take 1 to 3 hours and require a laboratory setting, and lateral flow assays lack the accuracy needed for quantitative cannabis intoxication detection. BreviTest Technologies LLC is developing a portable analyzer to perform a rapid, quantitative ELISA test within a 10-minute run time. The sample is loaded into a discontinuous microfluidics cartridge, and a robotic mechanism controls the movement of antibody-conjugated magnetic nanoparticles through successive fluid wells, where enhanced mixing patterns substantially reduce the time required for each ELISA step. This innovative approach enables the implementation of a rapid, portable, fully automated ELISA test with accuracy comparable to a standard laboratory ELISA. In this SBIR Phase I project, BreviTest will partner with Cayman Chemical Company to develop a THC ELISA test using the BreviTest robotic analyzer, with the following Specific Aims: 1) Develop and produce discontinuous microfluidic cartridges with layman-operable sample port. The type and quantity of magnetic nanoparticles will be determined for optimal reagent mixing and transit parameters, and the design and validation will be completed for a sampling tool for metering 20 µL of sample fluid. Design of the cartridge will be optimized for stability, consistency, and compatibility with
biological materials. 2) Develop curbside ELISA test to quantitatively measure THC in oral fluid. BreviTest will collaborate with Cayman Chemical to screen commercially available clones to generate an optimized antibody for THC detection. Antibodies will be conjugated to magnetic nanoparticles via streptavidin-biotin linkages, for use in the BreviTest analyzer. Optimization of reagent concentrations and analyzer parameters will be performed, along with statistical validation of dynamic range, specificity, and sensitivity. The completion of these proof-of-concept studies will demonstrate the ability of the BreviTest portable ELISA analyzer to measure THC concentration in oral fluid samples, at concentrations relevant to curbside intoxication analysis. This work will lay the foundation for further Phase II studies including fied and clinical testing of a rapid THC intoxication assay and additional validation testing towards a defined 510(k) clearance by the FDA.
描述(由申请人提供):执法官员,工作场所药物检测计划和药物滥用领域的研究人员缺乏快速,易于部署的工具来测量目前的大麻(大麻)中毒。酶联免疫吸附试验(ELISA)是一种用于检测尿液或血液中δ-9-四氢大麻酚(THC)水平的成熟大麻检测方法;然而,现场获取尿液或血液样本的物流是当前THC ELISA的主要限制,特别是对于驾驶员的路边测试。路边检测最可行的候选样本是口腔液,因为它是一种微创采样途径,并且口腔液中THC浓度的药代动力学(半衰期为1.5小时)与血清相似;然而,这种方法的主要障碍是缺乏快速、定量的THC免疫测定法。传统的基于平板的ELISA检测可能需要1至3小时,并且需要实验室设置,并且侧流检测缺乏定量大麻中毒检测所需的准确性。BreviTest Technologies LLC正在开发一种便携式分析仪,可在10分钟内进行快速定量ELISA测试。将样品加载到不连续的微流体盒中,并且机器人机构控制抗体缀合的磁性纳米颗粒通过连续的流体威尔斯孔的移动,其中增强的混合模式实质上减少了每个ELISA步骤所需的时间。这种创新的方法能够实现快速、便携、全自动化的ELISA检测,其准确性可与标准实验室ELISA相媲美。在这个SBIR第一阶段项目中,BreviTest将与Cayman Chemical Company合作,使用BreviTest机器人分析仪开发THC ELISA测试,具体目标如下:1)开发和生产具有非专业人员可操作样品端口的不连续微流体盒。将确定磁性纳米颗粒的类型和数量,以获得最佳的试剂混合和运输参数,并将完成用于计量20 µL样品流体的采样工具的设计和验证。将对笔芯的设计进行优化,以实现稳定性、一致性和与
生物材料。2)建立ELISA检测口腔液中THC的方法。BreviTest将与Cayman Chemical合作,筛选商用克隆,以生成用于THC检测的优化抗体。抗体将通过链霉亲和素-生物素连接与磁性纳米颗粒偶联,用于BreviTest分析仪。将对试剂浓度和分析仪参数进行优化,同时沿着对动态范围、特异性和灵敏度进行统计学验证。这些概念验证研究的完成将证明BreviTest便携式ELISA分析仪在与路边中毒分析相关的浓度下测量口腔液样本中THC浓度的能力。这项工作将为进一步的II期研究奠定基础,包括快速THC中毒检测的现场和临床测试以及FDA规定的510(k)许可的额外验证测试。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(6)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL JOHN HEFFERNAN其他文献
MICHAEL JOHN HEFFERNAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL JOHN HEFFERNAN', 18)}}的其他基金
Bedside right-heart catheterization for early diagnosis and more effective management of patients with heart failure and primary pulmonary hypertension
床边右心导管检查可对心力衰竭和原发性肺动脉高压患者进行早期诊断和更有效的治疗
- 批准号:
10696663 - 财政年份:2023
- 资助金额:
$ 22.44万 - 项目类别:
Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery
子宫壁膜锚定装置用于预防胎儿镜手术后子宫膜过早破裂
- 批准号:
10301644 - 财政年份:2021
- 资助金额:
$ 22.44万 - 项目类别:
Sensitive and Portable Physician Office-Based Urine Analyzer to Tackle Prescription Drug Abuse
灵敏的便携式医生办公室尿液分析仪可解决处方药滥用问题
- 批准号:
9256099 - 财政年份:2017
- 资助金额:
$ 22.44万 - 项目类别:
Sensitive and Portable Physician Office-Based Urine Analyzer to Tackle Prescription Drug Abuse
灵敏的便携式医生办公室尿液分析仪可解决处方药滥用问题
- 批准号:
9884752 - 财政年份:2017
- 资助金额:
$ 22.44万 - 项目类别:
Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery
子宫壁膜锚定装置用于预防胎儿镜手术后子宫膜过早破裂
- 批准号:
9981774 - 财政年份:2017
- 资助金额:
$ 22.44万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 22.44万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 22.44万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 22.44万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 22.44万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 22.44万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 22.44万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 22.44万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 22.44万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 22.44万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 22.44万 - 项目类别: